TABLE 1.
Demographics and baseline characteristics.
| MCI due to AD | ||
|---|---|---|
|
AGB101 (N = 18) |
Placebo (N = 26) |
|
| Age at screening (years) | 68.94 (7.0) | 70.04 (8.0) |
| Sex, n (%) | ||
| Male | 11 (61.1) | 10 (38.5) |
| Female | 7 (38.9) | 16 (61.5) |
| Race, n (%) | ||
| White | 17 (94.4) | 24 (92.3) |
| Black or African American | 1 (5.6) | 2 (7.7) |
| American Indian or Alaska Native | 0 (0) | 0 (0) |
| CDR | ||
| Sum of Boxes | 2.39 (1) | 2.71 (1) |
| Global Score | 0.5 (0.1) | 0.5 (0.1) |
| MMSE Total Score | 26.2 (2) | 25.5 (2.2) |
| FAQ Total Score | 7.8 (7.4) | 6.6 (4.8) |
| BPS‐O | 0.3 (0.3) | 0.3 (0.2) |
| ISLT | ||
| Immediate Recall | 17.2 (4.7) | 14.8 (3.7) |
| Delayed Recall | 2.9 (1.1) | 2.8 (1.3) |
Notes: Values are mean ± standard deviation. Participants with MCI due to AD assigned to the AGB101 condition did not differ from those assigned to the placebo condition on any measure listed (all P > 0.05).
Abbreviations: AD, Alzheimer's disease; BPS‐O, Behavioral Pattern Separation Task – Objects; CDR, Clinical Dementia Rating; FAQ, Functional Activities Questionnaire; ISLT, International Shopping List Test; MCI, mild cognitive impairment; MMSE, Mini‐Mental State Examination.